UK Companies Explore Marijuana Derivatives
Pharmaceutical Executive
Current lawmakers make frown on cannabis use, but for thousands of years people used it to treat conditions as diverse as rheumatism, convulsions, tumors, and pain. Now the small, private UK company Oxford Natural Products has completed Phase I trials on a cannabis derivative for treating post-operative and cancer pain.
Current lawmakers make frown on cannabis use, but for thousands of years people used it to treat conditions as diverse as rheumatism, convulsions, tumors, and pain. Now the small, private UK company Oxford Natural Products has completed Phase I trials on a cannabis derivative for treating post-operative and cancer pain.
ONP-04 is a pro-drug-an inactive substance that converts to the active form in the body-of tetrahydrocannabinol (THC), a major active ingredient of cannabis, formulated as a suppository. The Phase I trial, carried out by Inveresk Research, showed that delivering the product through a suppository increased bioavailability, with steadier release of the active ingredient. It also caused less liver damage than the US-licensed oral THC product, Marinol. A further advantage of rectal over oral administration is that it is much easier to administer to cancer patients, who often experience serious nausea and vomiting.
ONP licensed the active ingredient, THC hemi-succinate, from the University of Mississippi, which is the only legal producer of cannabis in the United States. ONP is now looking for a development partner to advance the medicine to Phase III.
One other UK company is working on cannabis as a medicine. GW Pharmaceuticals is developing a whole extract of the plant to treat multiple sclerosis and neuropathic pain. It has several Phase III trials underway.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
